| Not Yet Recruiting | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addit NCT07298577 | Siriraj Hospital | N/A |
| Recruiting | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV NCT07037277 | Atea Pharmaceuticals, Inc. | Phase 3 |
| Not Yet Recruiting | Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina. NCT06373198 | Hospital El Cruce | — |
| Completed | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV NCT05904470 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Epidemiology of Occult Hepatitis C Virus Infection in Patients Born Before 1969 in the Hospital Setting: a Spo NCT05813691 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy i NCT05870969 | Ruijin Hospital | — |
| Unknown | Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera NCT03882307 | Assiut University | EARLY_Phase 1 |
| Unknown | A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to E NCT04428346 | Kirby Institute | N/A |
| Active Not Recruiting | Enhancing Hepatitis C Testing and Treatment Among People Who Inject Drugs Attending Needle and Syringe Program NCT04014179 | Kirby Institute | N/A |
| Completed | Linkage to Care for Persons with Hep C Infection NCT05397067 | Carilion Clinic | N/A |
| Unknown | Possible Differences in HCC Course Depending on DAA Treatment NCT05376943 | Medical University of Warsaw | — |
| Active Not Recruiting | Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy NCT05140941 | Catherine Anne Chappell | Phase 4 |
| Recruiting | Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs NCT04943588 | Queen Mary University of London | — |
| Withdrawn | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects NCT04309734 | Atea Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals NCT05062408 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Completed | The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Viru NCT04774107 | PharmaEssentia | Phase 1 |
| Completed | HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels NCT04610762 | Centre Hospitalier Universitaire Saint Pierre | — |
| Completed | Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir NCT04382404 | Catherine Anne Chappell | Phase 1 |
| Completed | The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Stud NCT03987503 | University of California, San Francisco | Phase 4 |
| Terminated | Rapid HCV RNA Testing and LInkage to Care NCT04302948 | University of New Mexico | N/A |
| Unknown | Evaluating the Chain of Addiction Care (CAC) NCT05401136 | Radboud University Medical Center | — |
| Unknown | Re-engaging Patients With Hepatitis C Into Care NCT04029246 | Glasgow Royal Infirmary | N/A |
| Completed | Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Rece NCT03740906 | Kirby Institute | — |
| Unknown | Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study NCT03888729 | Partners in Health | Phase 4 |
| Unknown | Prolonged Release Pirfenidone for Advanced Residual Liver Fibrosis (MINERVA). NCT05542615 | University of Guadalajara | Phase 2 |
| Completed | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection NCT04019717 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Completed | Evaluation of Dried Blood Spot for HCV RNA Testing NCT03896087 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Unknown | SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepat NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2 / Phase 3 |
| Terminated | ATTIC - Access To Treat in the Community NCT03797066 | King's College Hospital NHS Trust | Phase 4 |
| Unknown | Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C NCT04952207 | Qing XIe | — |
| Completed | Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy NCT03903185 | Ain Shams University | Phase 1 / Phase 2 |
| Unknown | Eliminating HCV Infection Among PWUD NCT05474781 | Vancouver Infectious Diseases Centre | — |
| Completed | Voices From the Black Community: Hepatitis C Research Participation NCT04202081 | University of North Carolina, Chapel Hill | — |
| Unknown | Hepatitis C Surveillance With Linkage to Care of Patients From Non-ID Departments in Jiangsu NCT03772002 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Completed | Eight Weeks Sofosbovir/Ledipasvir in HCV Infected Children Aged 4 to 10 Years NCT03764345 | National Liver Institute, Egypt | N/A |
| Completed | Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients NCT03880682 | Istanbul University | — |
| Active Not Recruiting | People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral A NCT03520660 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 4 |
| Completed | Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings NCT03343925 | Kirby Institute | — |
| Completed | Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 NCT03578640 | King Fahad Medical City | Phase 3 |
| Completed | Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside NCT03513796 | NHS Tayside | — |
| Completed | Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia NCT03594838 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Completed | Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children NCT05091008 | Mansoura University Children Hospital | Phase 2 |
| Completed | Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [A NCT03480932 | Johns Hopkins Bloomberg School of Public Health | Phase 2 / Phase 3 |
| Unknown | Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy NCT03549312 | Saskatchewan Health Authority - Regina Area | Phase 4 |
| Completed | Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection NCT03057847 | Elizabeth Krans, MD | Phase 4 |
| Unknown | Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infe NCT03551002 | University of California, San Diego | — |
| Terminated | MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV NCT03003338 | Hannover Medical School | Phase 4 |
| Completed | A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic NCT03235154 | Community Research Initiative of New England | Phase 4 |
| Unknown | Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting NCT03551444 | Ain Shams University | Phase 3 |
| Terminated | Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment NCT03207399 | Duke University | Phase 4 |
| Completed | Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients NCT03413696 | University of California, San Diego | — |
| Completed | Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients NCT03117569 | Kirby Institute | Phase 3 |
| Unknown | Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence NCT03164902 | Proteus Digital Health, Inc. | N/A |
| Completed | Study of AT-527 in Healthy and HCV-Infected Subjects NCT03219957 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Unknown | Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral NCT03170076 | Assiut University | — |
| Recruiting | Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan NCT03200379 | Kaohsiung Medical University Chung-Ho Memorial Hospital | — |
| Completed | 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis NCT03186365 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 3 |
| Completed | KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C NCT03995485 | Kawin Technology Share-holding Co., Ltd. | Phase 3 |
| Completed | Integrated Treatment of Hepatitis C Virus Infection NCT03155906 | Haukeland University Hospital | N/A |
| Completed | Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers NCT03038763 | University of Pennsylvania | — |
| Completed | Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir NCT03063879 | Tehran University of Medical Sciences | Phase 4 |
| Unknown | Curing HCV in Incarcerated Patients NCT03018353 | San Francisco Department of Public Health | Phase 4 |
| Completed | Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia NCT03342261 | Hospices Civils de Lyon | — |
| Completed | Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C NCT03416491 | Kawin Technology Share-holding Co., Ltd. | Phase 2 |
| Completed | A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvi NCT02993250 | Janssen Pharmaceutical K.K. | Phase 2 |
| Unknown | Eliminate Hepatitis C/EC Partnership Evaluation Protocol NCT04061551 | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | N/A |
| Completed | Hepatitis C Virus(HCV) Heart and Lung Study NCT02858180 | Duke University | Phase 4 |
| Completed | Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chroni NCT02765490 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Anticipated and Perceived Benefits Following Hepatitis C Treatment NCT03000023 | University of North Carolina, Chapel Hill | — |
| Completed | Transforming the Cascade Of Hepatitis C Care NCT03226509 | University of Pittsburgh | — |
| Unknown | Cohort Study on People Who Inject Drugs in Senegal NCT03459768 | French National Agency for Research on AIDS and Viral Hepatitis | — |
| Completed | Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C NCT03453346 | Kawin Technology Share-holding Co., Ltd. | N/A |
| Completed | A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Inf NCT02498015 | Kirby Institute | Phase 4 |
| Completed | Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection NCT02707991 | Johns Hopkins University | N/A |
| Completed | Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon NCT02804386 | PharmEvo Pvt Ltd | Phase 4 |
| Terminated | Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genot NCT02759315 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection NCT02660905 | Ottawa Hospital Research Institute | Phase 3 |
| Completed | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC NCT02771405 | National Hepatology & Tropical Medicine Research Institute | Phase 3 |
| Completed | Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients NCT02969668 | Universitätsklinikum Hamburg-Eppendorf | — |
| Completed | A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate NCT02666352 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection NCT02597166 | University Health Network, Toronto | Phase 3 |
| Unknown | Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C NCT02639585 | Pusan National University Hospital | Phase 4 |
| Completed | Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirr NCT02624063 | Federal University of São Paulo | Phase 4 |
| Completed | The Patient-Reported Outcomes Project of HCV-TARGET NCT02601820 | University of North Carolina, Chapel Hill | — |
| Completed | Directly Observed Therapy for HCV in Chennai, India NCT02541409 | Johns Hopkins Bloomberg School of Public Health | Phase 2 |
| Withdrawn | Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism NCT02292966 | Kirby Institute | Phase 4 |
| Terminated | Primary Prevention Hepatocellular Carcinoma by Metformin NCT02319200 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages NCT04177043 | Egyptian Liver Hospital | Phase 4 |
| Completed | Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO NCT02461745 | Kaiser Permanente | Phase 4 |
| Completed | A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regim NCT02421211 | Janssen Sciences Ireland UC | Phase 2 |
| Completed | Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection NCT03119025 | Russian Academy of Medical Sciences | Phase 1 / Phase 2 |
| Completed | Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection NCT02340962 | TaiGen Biotechnology Co., Ltd. | Phase 2 |
| Completed | Hepatitis C Virus Infection in Patients With Hemoglobinopathies NCT03149289 | Società Italiana Talassemie ed Emoglobinopatie | — |
| Completed | A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatiti NCT02268864 | Janssen-Cilag International NV | Phase 2 |
| Completed | An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C NCT01679834 | Hoffmann-La Roche | — |
| Unknown | Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy NCT02469012 | University of Wuerzburg | N/A |
| Completed | An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With NCT02262728 | Janssen Research & Development, LLC | Phase 2 |
| Withdrawn | A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C NCT02206932 | University of California, San Francisco | Phase 4 |
| Terminated | An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a NCT02118597 | Hoffmann-La Roche | — |
| Completed | Observational Study in HCV Chronic Infection NCT01945008 | Istituto Superiore di Sanità | — |
| Terminated | Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic H NCT02120274 | Federal University of São Paulo | Phase 4 |
| Completed | Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Pa NCT03057236 | University of North Carolina, Chapel Hill | N/A |
| Completed | Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection NCT01147107 | University of Hawaii | Phase 4 |
| Completed | Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of C NCT02027116 | GeneOne Life Science, Inc. | Phase 1 |
| Completed | Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects NCT02014571 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclat NCT01938625 | Janssen R&D Ireland | Phase 2 |
| Completed | Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 NCT01994486 | University of Florida | Phase 2 |
| Completed | Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy NCT02060058 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 3 |
| Completed | Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin i NCT01945294 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection NCT01846832 | Janssen-Cilag International NV | Phase 3 |
| Completed | Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C NCT01925183 | Markus Peck-Radosavljevic | Phase 4 |
| Completed | Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) NCT01919125 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients NCT01871662 | Rottapharm | Phase 2 / Phase 3 |
| Completed | A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients NCT01928147 | Presidio Pharmaceuticals, Inc. | Phase 1 |
| Completed | A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Es NCT01879462 | GlaxoSmithKline | Phase 1 |
| Unknown | Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus R NCT01872936 | Santaris Pharma A/S | Phase 2 |
| Completed | Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in NCT01907724 | Merck Sharp & Dohme LLC | Phase 1 |
| Withdrawn | Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients NCT01858961 | Boehringer Ingelheim | Phase 3 |
| Completed | New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C NCT01888900 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribav NCT01749150 | Hoffmann-La Roche | Phase 2 |
| Completed | Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 NCT01849562 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chr NCT01830127 | Boehringer Ingelheim | Phase 2 |
| Completed | DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) NCT01743521 | Kirby Institute | Phase 4 |
| Terminated | Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) NCT01606800 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Combination Therapy for Chronic Hepatitis C Infection NCT01805882 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1 NCT01732796 | Boehringer Ingelheim | Phase 3 |
| Completed | Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir NCT01818856 | Hospitales Universitarios Virgen del Rocío | Phase 1 |
| Completed | Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepati NCT01728324 | Boehringer Ingelheim | Phase 3 |
| Terminated | An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chron NCT01798576 | Hoffmann-La Roche | — |
| Completed | An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepa NCT01725529 | Janssen R&D Ireland | Phase 3 |
| Terminated | 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporiv NCT02465203 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infectio NCT01608737 | Boehringer Ingelheim | Phase 3 |
| Completed | A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-2 NCT01685203 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Dose Ranging of GSK2336805 in Combination Therapy NCT01648140 | GlaxoSmithKline | Phase 2 |
| Completed | A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Ge NCT01591460 | Hoffmann-La Roche | Phase 4 |
| Completed | Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients NCT01636778 | GlaxoSmithKline | Phase 2 |
| Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR NCT01750216 | Hoffmann-La Roche | — |
| Completed | Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV NCT02690103 | Cairo University | Phase 2 |
| Unknown | Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2) NCT01760148 | Junqi Niu | — |
| Completed | An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection NCT01671046 | Hoffmann-La Roche | — |
| Withdrawn | A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chr NCT01579019 | Hoffmann-La Roche | Phase 2 |
| Completed | A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 NCT01364090 | Kirby Institute | Phase 4 |
| Completed | ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Witho NCT01628094 | Hoffmann-La Roche | Phase 2 |
| Completed | Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa NCT02439918 | Université de Sherbrooke | — |
| Completed | Telaprevir Open-Label Study in Co-Infected Patients NCT01500616 | Janssen-Cilag International NV | Phase 3 |
| Completed | Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chroni NCT01544920 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With NCT01604291 | Hoffmann-La Roche | — |
| Completed | Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C P NCT01544582 | Merck Sharp & Dohme LLC | — |
| Completed | Gilead Sustained Virologic Response (SVR) Registry NCT01457755 | Gilead Sciences | — |
| Completed | Drug-drug Interaction of BI 201335 and Microgynon NCT01570244 | Boehringer Ingelheim | Phase 1 |
| Terminated | A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males NCT01554189 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment NCT01483742 | Hoffmann-La Roche | Phase 2 |
| Completed | Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients NCT01525628 | Boehringer Ingelheim | Phase 1 |
| Completed | This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Pa NCT01528735 | Boehringer Ingelheim | Phase 2 |
| Completed | An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patient NCT01508130 | Hoffmann-La Roche | — |
| Terminated | Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614) NCT01425190 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients NCT02057003 | Valme University Hospital | — |
| Completed | A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chr NCT01585324 | Hoffmann-La Roche | Phase 4 |
| Completed | Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected NCT01508156 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation NCT01579162 | HepQuant, LLC | N/A |
| Terminated | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic NCT01554085 | Alios Biopharma Inc. | Phase 1 |
| Completed | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic NCT01590407 | Alios Biopharma Inc. | Phase 1 |
| Completed | A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response NCT01457768 | Gilead Sciences | — |
| Completed | An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hep NCT01609049 | Hoffmann-La Roche | — |
| Terminated | Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis NCT01440595 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior NCT01459913 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Completed | A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis NCT01482403 | Hoffmann-La Roche | Phase 2 |
| Completed | Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063) NCT01390844 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Viru NCT01587586 | PharmaEssentia | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patient NCT01523990 | TaiGen Biotechnology Co., Ltd. | Phase 1 |
| Unknown | Prediction of Liver-related Outcomes After HCV Cure NCT04460157 | Hospital Universitario de Valme | — |
| Completed | A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1 NCT01448200 | Presidio Pharmaceuticals, Inc. | Phase 1 |
| Completed | Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders NCT01405560 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients Wit NCT01447446 | Hoffmann-La Roche | — |
| Completed | Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human NCT01399619 | Boehringer Ingelheim | Phase 3 |
| Completed | GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hep NCT01435226 | Gilead Sciences | Phase 2 |
| Completed | Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection NCT01435044 | Gilead Sciences | Phase 2 |
| Completed | Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir NCT02113631 | Louis Stokes VA Medical Center | N/A |
| Completed | Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed A NCT01405937 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in NCT01675427 | Hoffmann-La Roche | Phase 4 |
| Completed | Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hep NCT01439373 | GlaxoSmithKline | Phase 2 |
| Completed | GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Gen NCT01356160 | Gilead Sciences | Phase 2 |
| Completed | Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Exp NCT01371578 | Gilead Sciences | Phase 2 |
| Completed | The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic P NCT01770483 | Services Institute of Medical Sciences, Pakistan | Phase 4 |
| Completed | Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (M NCT01371604 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chron NCT01353911 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis NCT01370642 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C NCT01705717 | Hoffmann-La Roche | — |
| Completed | Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in NCT01358864 | Boehringer Ingelheim | Phase 3 |
| Completed | An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Peg NCT01392742 | Hoffmann-La Roche | — |
| Completed | A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C NCT01331850 | Hoffmann-La Roche | Phase 2 |
| Terminated | Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatit NCT02309086 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 1 / Phase 2 |
| Completed | A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection NCT01366638 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis NCT01353248 | Gilead Sciences | Phase 2 |
| Completed | A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis NCT01659567 | Hoffmann-La Roche | — |
| Completed | The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients NCT01335230 | University of Cincinnati | — |
| Completed | Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen NCT01332955 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Completed | Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 NCT01329978 | Gilead Sciences | Phase 2 |
| Completed | A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa NCT01337375 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in I NCT01278134 | Hoffmann-La Roche | Phase 2 |
| Completed | A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous NCT01288209 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Ch NCT01447420 | Hoffmann-La Roche | Phase 4 |
| Completed | A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients NCT01292239 | Janssen Pharmaceutical K.K. | Phase 3 |
| Terminated | Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzym NCT01226797 | Pfizer | Phase 2 |
| Completed | A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients NCT01903954 | Hoffmann-La Roche | Phase 2 |
| Completed | An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C NCT03423641 | Kaiser Permanente | — |
| Completed | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment N NCT01316237 | Gilead Sciences | Phase 1 |
| Completed | A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Ba NCT01290731 | Janssen Pharmaceutical K.K. | Phase 3 |
| Unknown | Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian NCT01758939 | Cairo University | — |
| Unknown | Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C NCT01900886 | Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria | — |
| Completed | A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Nai NCT01220947 | Hoffmann-La Roche | Phase 2 |
| Completed | Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With NCT01884402 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Completed | A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Withou NCT01271790 | Gilead Sciences | Phase 2 |
| Terminated | An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological NCT01168856 | Hoffmann-La Roche | — |
| Active Not Recruiting | Prospective Observational Study of Disease Progression in Chronic Hepatitis C NCT02011932 | Beijing YouAn Hospital | — |
| Completed | The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System NCT01206933 | George Washington University | — |
| Completed | Biliverdin Reductase A in Chronic Hepatitis C Virus Infection NCT01112033 | Charles University, Czech Republic | — |
| Unknown | To Study the Efficacy and Safety of Renessans in Chronic HCV Patients NCT01463592 | MTI Medical Private Limited, Pakistan | Phase 3 |
| Unknown | Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection NCT01001754 | ZymoGenetics | Phase 2 |
| Completed | Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic NCT01132313 | Boehringer Ingelheim | Phase 2 |
| Completed | VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telapre NCT01054573 | Janssen Infectious Diseases BVBA | Phase 3 |
| Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chroni NCT01416610 | Hoffmann-La Roche | — |
| Completed | A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Pati NCT01087944 | Hoffmann-La Roche | Phase 1 |
| Completed | An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With NCT01200225 | Hoffmann-La Roche | — |
| Withdrawn | Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients NCT01062659 | University of Ulm | — |
| Completed | A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients W NCT01057667 | Hoffmann-La Roche | Phase 2 |
| Completed | A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECI NCT01280656 | Hoffmann-La Roche | — |
| Completed | Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction NCT01023035 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterfero NCT01296971 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Pati NCT01033448 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Othe NCT00943761 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | ADHEPTA Study: Adherence Questionnaire in Hepatitis C NCT00998621 | Fundacion IMIM | — |
| Completed | An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Lo NCT01344889 | Hoffmann-La Roche | — |
| Completed | A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chr NCT00963885 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With NCT01185860 | Hoffmann-La Roche | Phase 1 |
| Completed | 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV) NCT00953589 | Biolex Therapeutics, Inc. | Phase 2 |
| Completed | A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon NCT00996476 | Janssen Pharmaceutical K.K. | Phase 2 |
| Completed | Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon NCT00910624 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Interferon-alpha Lozenges for Prevention of Relapse in Hepatitis C NCT00695019 | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | Phase 2 |
| Completed | Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribaviri NCT01098097 | Merck Sharp & Dohme LLC | — |
| Completed | Interferon α 2b Pharmacovigilance Study NCT01841775 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 4 |
| Completed | 4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients NCT00905632 | Boehringer Ingelheim | Phase 1 |
| Completed | An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatiti NCT02557646 | Hoffmann-La Roche | — |
| Completed | A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis NCT00800735 | Hoffmann-La Roche | Phase 3 |
| Completed | Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) NCT00863109 | Merck Sharp & Dohme LLC | — |
| Completed | Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatme NCT00704405 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis NCT02556307 | Hoffmann-La Roche | — |
| Completed | Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV NCT00863239 | Biolex Therapeutics, Inc. | Phase 2 |
| Withdrawn | Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis C NCT00782301 | ViiV Healthcare | Phase 4 |
| Completed | Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV NCT02027493 | National Liver Institute, Egypt | N/A |
| Completed | Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Ge NCT00845065 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in NCT00704756 | Merck Sharp & Dohme LLC | — |
| Terminated | Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Prac NCT00725842 | Merck Sharp & Dohme LLC | — |
| Terminated | Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients NCT00803309 | HepNet Study House, German Liverfoundation | Phase 4 |
| Completed | A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (R NCT00801255 | Hoffmann-La Roche | Phase 1 |
| Completed | POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or NCT00700401 | Hoffmann-La Roche | — |
| Completed | A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chron NCT00797745 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) NCT00788918 | Aarhus University Hospital | N/A |
| Completed | A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previo NCT00703118 | Tibotec BVBA | Phase 3 |
| Completed | Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2) NCT00774397 | Boehringer Ingelheim | Phase 2 |
| Completed | A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 NCT01429792 | Hoffmann-La Roche | Phase 4 |
| Completed | Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study NCT00705432 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribav NCT00708500 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatit NCT00718172 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) NCT00724451 | Merck Sharp & Dohme LLC | — |
| Terminated | ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin NCT00856024 | Merck Sharp & Dohme LLC | — |
| Completed | A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in P NCT00623428 | Hoffmann-La Roche | Phase 3 |
| Completed | Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV NCT00705224 | Merck Sharp & Dohme LLC | — |
| Completed | Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) NCT00723645 | Merck Sharp & Dohme LLC | — |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Tre NCT00545233 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hep NCT00561353 | Tibotec Pharmaceuticals, Ireland | Phase 2 |
| Completed | Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patient NCT00686777 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis NCT01066819 | Hoffmann-La Roche | — |
| Completed | Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection NCT00565539 | ZymoGenetics | Phase 1 |
| Completed | A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepa NCT00561015 | Tibotec BVBA | Phase 2 |
| Completed | Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic NCT00724464 | Merck Sharp & Dohme LLC | — |
| Completed | Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infec NCT02176525 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Comp NCT00517439 | Hoffmann-La Roche | Phase 2 |
| Completed | Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) NCT00724373 | Merck Sharp & Dohme LLC | — |
| Completed | Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients NCT00553930 | Sociedad Andaluza de Enfermedades Infecciosas | Phase 4 |
| Completed | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver NCT00516321 | GlaxoSmithKline | Phase 3 |
| Completed | Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver NCT00529568 | GlaxoSmithKline | Phase 3 |
| Completed | PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatit NCT01066793 | Hoffmann-La Roche | — |
| Completed | Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitu NCT00725751 | Merck Sharp & Dohme LLC | — |
| Completed | Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and NCT00793793 | Boehringer Ingelheim | Phase 1 |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failu NCT00474955 | Hoffmann-La Roche | Phase 4 |
| Completed | Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland NCT00473993 | Seidenberg, Arztpraxis A., M.D. | — |
| Completed | Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Gen NCT01081158 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02 NCT00761735 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Vir NCT00483938 | Hoffmann-La Roche | Phase 3 |
| Completed | Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver C NCT00687219 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatit NCT01070550 | Hoffmann-La Roche | — |
| Terminated | Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged T NCT00493805 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genoty NCT02716779 | Hoffmann-La Roche | Phase 2 |
| Terminated | Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Ch NCT00689390 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Completed | A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and P NCT02726022 | Hoffmann-La Roche | — |
| Completed | A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patien NCT00394277 | Hoffmann-La Roche | Phase 4 |
| Completed | Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Co NCT01908660 | Valme University Hospital | — |
| Completed | SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patie NCT00412334 | Hoffmann-La Roche | Phase 4 |
| Terminated | Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chron NCT00686881 | Merck Sharp & Dohme LLC | Phase 3 |